人静脈注用免疫グロブリン
人静脈注用免疫グロブリン（hIVIG）は、犬の重篤な免疫介在性疾患の治療に使用される精製血液製剤です。**臨床のポイント：** 免疫介在性血小板減少症（IMT）における有効性はビンクリスチンと同等ですが、免疫介在性溶血性貧血（IMHA）での使用には依然として議論があります。> **警告：** 他の治療法が失敗した例外的なケースにのみ使用を限定すべきです。
作用機序: The drug has both immediate and long-term immunomodulatory effects, though exact mechanisms are not fully elucidated. * **Immediate effects:** Binding to **Fc receptors** on macrophages (preventing phagocytosis of opsonized cells) and providing **anti-idiotype antibodies**. * **Long-term effects:** Reacts with membrane receptors on **T cells**, **B cells**, and **monocytes** → alters immune system autoregulation, reduces autoreactivity, and induces tolerance to self.
動物種別の用量
- Severe immune-mediated diseases (e.g., IMT, acute polyradiculoneuritis) · 0.5-1.0 g/kg (Higher doses of up to 2.2 g/kg are used in some studies) · IV · Administered over 6-8 hours · Single infusion · Administer slowly over 6-8 hours.
用量は獣医療従事者向けの臨床リファレンスです。必ず最新の添付文書と個々の患者で確認してください。
投与経路
禁忌
- Patients with increased plasma protein levels (hyperproteinaemia)
有害事象
- Anaphylactic reactions (theoretical risk, though not widely recorded in dogs)
薬物相互作用
- Highly protein-bound drugs · Use with care due to potential binding displacement or alterations in plasma protein dynamics · moderate
- Vaccines · May interfere with the immune response to vaccination; use with care · moderate
モニタリング
- Plasma protein levels
- Signs of anaphylaxis during infusion
- Clinical signs of immune-mediated disease resolution (e.g., platelet counts)
過量投与
No specific overdose information is provided in the monograph. However, excessive administration may lead to severe hyperproteinaemia, hyperviscosity syndrome, and volume overload.
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。